This semaglutide-based medication, approved for weight loss in individuals with increased body mass index, works by suppressing appetite
PlexusDx providers use this personalized approach to match you with the dose that delivers results without unnecessary side effects
The very low rates of hypoglycemia are an additional advantage in vulnerable patients, such as the elderly or patients who live alone
While many people anticipate digestive changes, some report feeling a general soreness or specific muscle discomfort
Yes, variants in the GLP1R gene (e.g., rs6923761) have been associated with differences in weight loss response to GLP-1 medications in clinical studies
Last reviewed: July 6, 2026 Last updated: July 6, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations